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A Response to Christopher Hood: ‘The ethics of personal genetic 
profiling’ 
 
RICHARD TUTTON AND ADAM HEDGECOE1 
 
One aspect of the recently published Nuffield Council on Bioethics’ report on 
Medical Profiling and Online Medicine centred on the development of direct-to-
consumer (DTC) personal genomic services, and is the focus of Hood’s commentary 
in this issue of GSP. We have been prompted to make a number of comments in 
response to this piece (rather than to the report in its entirety). We would first like to 
state clearly that the work of the Nuffield group is welcomed and its report is a very 
useful contribution to ongoing discussions amongst academics, policy makers, and 
public interest groups about developments in the personalisation and online provision 
of various healthcare products and services.  
 
Online services offering direct-to-consumer genetic testing have been around for 
about a decade or so now and have been growing in number. It is important to note 
that those companies which have tended to grab the headlines in the last few years, 
namely those offering personal genomics services such as 23andMe, Navigenics, 
deCODEMe, and Pathway Genomics, are only one part of a dynamic commercial 
sector in which companies have developed distinctive business models and specialise 
in different genetic testing services. A survey conducted by Cesagen in August 2010 
indicated that, at that time at least, there were 69 services offering genetic testing to 
consumers for a wide range of purposes. These included: providing information on 
future disease susceptibility and drug metabolism, diagnosing existing gene disorders, 
providing advice on physical exercise, nutrition and lifestyle choices based on 
analysis of DNA, and offering information about genetic relationships or ancestry. 
While Hood focuses exclusively on susceptibility testing services that provide 
estimates to individuals of their risk of developing future disease, many of the same 
companies as well as others also offer carrier and prenatal diagnostic testing to 
consumers. The market therefore is a heterogeneous one and this needs to be 
recognised by policy advisors in their investigations and recommendations.  
Determining the Problem and the Lack of Evidence  
Although we agree with Hood that there is "little evidence available about the number 
of people buying these services", we feel that the claim that there is little evidence 
about "the harms (or benefits) they experience from taking the tests" is inaccurate. 
While we may not have very much specific data on DTC testing yet, psychosocial 
research into the impact of genetic susceptibility testing goes back over a decade. 
While this research highlights the complex and unpredictable nature of people's 
response to this kind of information, it is also clear that: “threat representations that 
include genetic causes are often seen as ones that are less controllable than threats 
with behavioural or environmental causes”.2 For example, in the case of counselling 
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designed to persuade people to give up smoking, “genetic feedback may heighten 
vulnerability and possibly promote distress, but may not immediately enhance quitting 
in most smokers”.3 This literature should not be neglected; indeed, it should be 
engaged with by policy advisors when considering the issue of DTC testing, to draw 
out its implications for society as a whole. The picture is further complicated by Bloss 
et al, who very recently reported that, based on their research, the impact on 
individuals’ health behaviour from the information they gain from a DTC personal 
genome service appears to be very limited.4  
Regulation and International Developments 
The focus of Hood’s commentary was very much the UK context, but of course these 
sociotechnical developments are international in character, especially given the 
widespread use of the internet to purchase DTC tests, and so the international context 
is also important. At the European Union level, the 1998 Directive on in vitro 
diagnostic medical devices (known as IVDD, 98/79/EC) sets a series of standards for 
the manufacture, supply, labelling, safety and performance of in vitro diagnostic 
medical devices, including genetic tests.5 The IVDD, however, has limited 
application in relation to DTC testing since it does not apply to ‘in-house’ tests 
developed by laboratories for their own use, which many DTC tests qualify as being, 
and defers to member states to set their own laws on the supply of medical devices. 
France, Switzerland and Germany have all made private genetic testing without 
physician approval illegal, while the UK and the Netherlands have not, so there are 
differing views amongst European countries. In June 2010 the European Commission 
opened a consultation on revising the IVDD and asked specifically whether additional 
requirements or restrictions for DTC genetic tests are required. This planned revision 
of the IVDD builds on work undertaken by the Global Harmonization Task Force 
(GHTF) which has developed a new risk classification scheme that could lead to new 
genetic tests being subject to independent premarket review.  
 
Furthermore, in 2008, the Council of Europe approved an additional protocol to the 
Convention on Human Rights and Biomedicine of 1997, which states that “clinical 
utility of a genetic test shall be an essential criterion for deciding to offer this test to a 
person or a group of persons” (article 6) and that “a genetic test for health purposes 
may only be performed under individualised medical supervision” (article 7).6 It is 
not clear that to date all signatories to the Convention have signed up to the new 
protocol, and it should be noted that the UK, along with 20 of the 47 members of the 
Council of Europe, has not signed and ratified the Convention.  
 
As Hogarth et al observed a few years ago: “It is unlikely that we will see the 
emergence of a common, harmonized approach to DTC testing”7 but in the last year 
we are beginning to see a more joined-up approach to DTC regulation from US and 
European Union authorities. Much depends on what the US authorities decide to do in 
relation to DTC genetic testing, since most of the industry is located in that country 
and we are awaiting the outcome of recent interventions by the US Food and Drug 
Administration in this area to see what will change in terms of how DTC tests are 
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regulated. However, with the launch of new companies in South Korea, Australia, and 
India, the personal genomics industry is becoming more globalised. It certainly looks 
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